RenovoRx, Inc.
RNXT
Rank in Stocks
#22462
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to... RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Share Price
$1.18
Last synced: 2026-11-09
Market Cap
$53.25M
Change (1 day)
4.42%
Change (1 year)
10.28%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade RenovoRx, Inc. (RNXT)
Category
Healthcare
Operating Margin for RenovoRx, Inc. (RNXT)
Operating Margin as of November 2026 TTM: -678.04%
According to RenovoRx, Inc.'s latest financial reports, its current operating margin (TTM) is -678.04%. At the end of 2025 the company had an operating margin of -1,113.98%.
Operating Margin history for RenovoRx, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -678.04% | -39.13% |
| 2025 | -1,113.98% | -95.63% |
| 2024 | -25,511.63% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.06% |
US
|
|
| -149.01% | -99.78% |
US
|
|
| 25.57% | -100.04% |
AU
|
|
| 31.23% | -100.05% |
BE
|
|
| 29.35% | -100.04% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about RenovoRx, Inc.'s operating margin
What is RenovoRx, Inc.'s operating margin?
RenovoRx, Inc.'s operating margin is -678.04%, as of Nov 2026.
What was RenovoRx, Inc.'s operating margin in 2025?
In 2025, RenovoRx, Inc.'s operating margin was -1,113.98%, compared with -25,511.63% in 2024.
How has RenovoRx, Inc.'s operating margin changed since 2020?
From 2020 to 2025, RenovoRx, Inc.'s operating margin was highest in 2023 (0.00%) and lowest in 2024 (-25,511.63%).
How does RenovoRx, Inc.'s operating margin compare with similar companies?
RenovoRx, Inc.'s operating margin (-678.04%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.